Mitiglinide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mitiglinide
Mitiglinide.svg
Systematic (IUPAC) name
(2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
oral
Identifiers
CAS Number 145375-43-5 N
ATC code A10BX08 (WHO)
PubChem CID 121891
DrugBank DB01252 YesY
ChemSpider 108739 YesY
UNII D86I0XLB13 YesY
KEGG D01854 YesY
ChEMBL CHEMBL471498 YesY
Chemical data
Formula C19H25NO3
Molar mass 315.41 g/mol
 NYesY (what is this?)  (verify)

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.[1]

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology[edit]

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage[edit]

Mitiglinide is delivered in tablet form.

References[edit]

External links[edit]